Metabolically unhealthy overweight individuals have high lysophosphatide levels, phospholipase activity, and oxidative stress

Minjoo Kim, Hye Jin Yoo, Juyeon Ko, Jong Ho Lee

Research output: Contribution to journalArticle

Abstract

Background & aims: Metabolically unhealthy overweight (MUO) individuals and metabolically healthy overweight (MHO) individuals differ in biomarkers of atherogenesis. Metabolomic approaches enable studies of the metabolic variables underlying these differences. Methods: We determined the metabolomes in plasma samples from 34 MUO and 34 MHO individuals matched for sex, age, and body mass index (BMI) to identify potential metabolic markers or pathways associated with atherogenic traits. Results: This analysis revealed that the MUO group had significantly higher levels of glycolic acid, 6 lysophosphatidylethanolamines (lysoPEs), and 12 lysophosphatidylcholines (lysoPCs). Although the two groups had similar total body fat percentages and lean body masses, MUO individuals had larger visceral fat areas (VFAs). They also had greater circulating lipoprotein-associated phospholipase A 2 (Lp-PLA 2 ) activity and higher levels of oxidized low-density lipoprotein (ox-LDL) and urinary 8-epi-prostaglandin F (8-epi-PGF ), reflecting higher risks for oxidative and lipid-related tissue damage. The following measures were positively correlated: VFA and ox-LDL; ox-LDL and Lp-PLA 2 activity; and lysoPC, lysoPE, and 8-epi-PGF levels. Chronic plasma lysoPC increases were associated with atherogenic traits, higher levels of mean ox-LDL, 8-epi-PGF , Lp-PLA 2 , and visceral fat accumulation in MUO compared to MHO individuals. Conclusions: This panel of plasma metabolites distinguishes MUO from MHO individuals and will enable future research on fat dysregulation and obesity.

Original languageEnglish
JournalClinical Nutrition
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Phospholipases
Oxidative Stress
1-Alkyl-2-acetylglycerophosphocholine Esterase
Prostaglandins F
Intra-Abdominal Fat
glycolic acid
Lysophosphatidylcholines
Metabolomics
Metabolome
Lipoproteins
Adipose Tissue
Atherosclerosis
Body Mass Index
Obesity
Biomarkers
Fats
Lipids
oxidized low density lipoprotein

All Science Journal Classification (ASJC) codes

  • Nutrition and Dietetics
  • Critical Care and Intensive Care Medicine

Cite this

@article{064b0b566dd740ae8eedf4275311d534,
title = "Metabolically unhealthy overweight individuals have high lysophosphatide levels, phospholipase activity, and oxidative stress",
abstract = "Background & aims: Metabolically unhealthy overweight (MUO) individuals and metabolically healthy overweight (MHO) individuals differ in biomarkers of atherogenesis. Metabolomic approaches enable studies of the metabolic variables underlying these differences. Methods: We determined the metabolomes in plasma samples from 34 MUO and 34 MHO individuals matched for sex, age, and body mass index (BMI) to identify potential metabolic markers or pathways associated with atherogenic traits. Results: This analysis revealed that the MUO group had significantly higher levels of glycolic acid, 6 lysophosphatidylethanolamines (lysoPEs), and 12 lysophosphatidylcholines (lysoPCs). Although the two groups had similar total body fat percentages and lean body masses, MUO individuals had larger visceral fat areas (VFAs). They also had greater circulating lipoprotein-associated phospholipase A 2 (Lp-PLA 2 ) activity and higher levels of oxidized low-density lipoprotein (ox-LDL) and urinary 8-epi-prostaglandin F 2α (8-epi-PGF 2α ), reflecting higher risks for oxidative and lipid-related tissue damage. The following measures were positively correlated: VFA and ox-LDL; ox-LDL and Lp-PLA 2 activity; and lysoPC, lysoPE, and 8-epi-PGF 2α levels. Chronic plasma lysoPC increases were associated with atherogenic traits, higher levels of mean ox-LDL, 8-epi-PGF 2α , Lp-PLA 2 , and visceral fat accumulation in MUO compared to MHO individuals. Conclusions: This panel of plasma metabolites distinguishes MUO from MHO individuals and will enable future research on fat dysregulation and obesity.",
author = "Minjoo Kim and Yoo, {Hye Jin} and Juyeon Ko and Lee, {Jong Ho}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.clnu.2019.04.025",
language = "English",
journal = "Clinical Nutrition",
issn = "0261-5614",
publisher = "Churchill Livingstone",

}

Metabolically unhealthy overweight individuals have high lysophosphatide levels, phospholipase activity, and oxidative stress. / Kim, Minjoo; Yoo, Hye Jin; Ko, Juyeon; Lee, Jong Ho.

In: Clinical Nutrition, 01.01.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Metabolically unhealthy overweight individuals have high lysophosphatide levels, phospholipase activity, and oxidative stress

AU - Kim, Minjoo

AU - Yoo, Hye Jin

AU - Ko, Juyeon

AU - Lee, Jong Ho

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background & aims: Metabolically unhealthy overweight (MUO) individuals and metabolically healthy overweight (MHO) individuals differ in biomarkers of atherogenesis. Metabolomic approaches enable studies of the metabolic variables underlying these differences. Methods: We determined the metabolomes in plasma samples from 34 MUO and 34 MHO individuals matched for sex, age, and body mass index (BMI) to identify potential metabolic markers or pathways associated with atherogenic traits. Results: This analysis revealed that the MUO group had significantly higher levels of glycolic acid, 6 lysophosphatidylethanolamines (lysoPEs), and 12 lysophosphatidylcholines (lysoPCs). Although the two groups had similar total body fat percentages and lean body masses, MUO individuals had larger visceral fat areas (VFAs). They also had greater circulating lipoprotein-associated phospholipase A 2 (Lp-PLA 2 ) activity and higher levels of oxidized low-density lipoprotein (ox-LDL) and urinary 8-epi-prostaglandin F 2α (8-epi-PGF 2α ), reflecting higher risks for oxidative and lipid-related tissue damage. The following measures were positively correlated: VFA and ox-LDL; ox-LDL and Lp-PLA 2 activity; and lysoPC, lysoPE, and 8-epi-PGF 2α levels. Chronic plasma lysoPC increases were associated with atherogenic traits, higher levels of mean ox-LDL, 8-epi-PGF 2α , Lp-PLA 2 , and visceral fat accumulation in MUO compared to MHO individuals. Conclusions: This panel of plasma metabolites distinguishes MUO from MHO individuals and will enable future research on fat dysregulation and obesity.

AB - Background & aims: Metabolically unhealthy overweight (MUO) individuals and metabolically healthy overweight (MHO) individuals differ in biomarkers of atherogenesis. Metabolomic approaches enable studies of the metabolic variables underlying these differences. Methods: We determined the metabolomes in plasma samples from 34 MUO and 34 MHO individuals matched for sex, age, and body mass index (BMI) to identify potential metabolic markers or pathways associated with atherogenic traits. Results: This analysis revealed that the MUO group had significantly higher levels of glycolic acid, 6 lysophosphatidylethanolamines (lysoPEs), and 12 lysophosphatidylcholines (lysoPCs). Although the two groups had similar total body fat percentages and lean body masses, MUO individuals had larger visceral fat areas (VFAs). They also had greater circulating lipoprotein-associated phospholipase A 2 (Lp-PLA 2 ) activity and higher levels of oxidized low-density lipoprotein (ox-LDL) and urinary 8-epi-prostaglandin F 2α (8-epi-PGF 2α ), reflecting higher risks for oxidative and lipid-related tissue damage. The following measures were positively correlated: VFA and ox-LDL; ox-LDL and Lp-PLA 2 activity; and lysoPC, lysoPE, and 8-epi-PGF 2α levels. Chronic plasma lysoPC increases were associated with atherogenic traits, higher levels of mean ox-LDL, 8-epi-PGF 2α , Lp-PLA 2 , and visceral fat accumulation in MUO compared to MHO individuals. Conclusions: This panel of plasma metabolites distinguishes MUO from MHO individuals and will enable future research on fat dysregulation and obesity.

UR - http://www.scopus.com/inward/record.url?scp=85064929003&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064929003&partnerID=8YFLogxK

U2 - 10.1016/j.clnu.2019.04.025

DO - 10.1016/j.clnu.2019.04.025

M3 - Article

AN - SCOPUS:85064929003

JO - Clinical Nutrition

JF - Clinical Nutrition

SN - 0261-5614

ER -